PureTech Health to Voluntarily Delist ADSs from Nasdaq to Concentrate Trading on LSE
On April 29, 2026, PureTech Health plc announced its intention to voluntarily delist its American Depositary Shares (ADSs) from the Nasdaq Stock Market and concentrate its trading on the London Stock Exchange (LSE). The company determined that maintaining a dual listing was no longer necessary as the substantial majority of its trading volume, liquidity, and price discovery occurs on the LSE. By simplifying its listing structure, PureTech aims to enhance operational efficiency, streamline overhead costs, and focus resources on its biotherapeutics portfolio. The company expects to file a Form 25 with the SEC around May 11, 2026, with the last day of trading on Nasdaq anticipated to be May 20, 2026. Following the delisting, PureTech intends to maintain a sponsored Level 1 ADR program for over-the-counter trading and will file a Form 15F to terminate its SEC reporting obligations. The LSE will remain the companyβs primary listing venue, aligning with its UK-centered governance framework and investor base.